Citations

Clear

3030 citation(s) found for "Susan, M".

Carney Complex, Peutz-Jeghers Syndrome, Cowden Disease, and Bannayan-Zonana Syndrome Share Cutaneous and Endocrine Manifestations, But Not Genetic Loci
Taymans, Susan E., Tomlinson, Ian , Marsh, Debbie J., Torpy, David J. , Giatzakis, Christoforos, Eccles, Diana M., Theaker, Jeffrey, Houlston, Richard S. , Blouin, Jean‐Louis , Basson, Craig T. , Carney, J. Aidan, Eccles, Diana , Stratakis, Constantine A. , Kirschner, Lawrence S. , Marsh, Debbie J., Eccles, Diana M., Antonarakis, Stylianos E. , Eng, Charis , Eccles, Diana , Houlston, Richard S

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 8, 2014 | Volume: 83 | Issue: 8 | Pages: 2972-2976

10.1210/jcem.83.8.5042 | PMID 9709978 Get It

Insulin-Like Growth Factor (IGF) Binding Protein-3 Potentiation of IGF Action Is Mediated through the Phosphatidylinositol-3-Kinase Pathway and Is Associated with Alteration in Protein Kinase B/AKT Sensitivity*
Conover, Cheryl A. , Bale, Laurie K., Durham, Susan K., Powell, D.R.

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 141 | Issue: 9 | Pages: 3098-3103

10.1210/endo.141.9.7660 | PMID 10965879 Get It

Thyroid Hormone Is Essential for Pituitary Somatotropes and Lactotropes*
Stahl, Justin H., Brinkmeier, Michelle L. , Greco, T. L. , Watkins‐Chow, Dawn E. , Campos‐Barros, Ángel , Lloyd, Ricardo V., Camper, Sally A. , Kendall, Susan K.

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 140 | Issue: 4 | Pages: 1884-1892

10.1210/endo.140.4.6627 | PMID 10098528 Get It

Associations between Cigarette Smoking, Hormone Therapy, and Folate Intake with Incident Colorectal Cancer by TP53 Protein Expression Level in a Population-Based Cohort of Older Women
Tillmans, Lori S. , Vierkant, Robert A. , Wang, Alice H., Samadder, N. Jewel , Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Cerhan, James R. , Slager, Susan L. , Limburg, Paul J. , Cerhan, James R , Vierkant, Robert A , Haile, Robert W , Potter, John D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 17, 2013 | Volume: 23 | Issue: 2 | Pages: 350-355

10.1158/1055-9965.epi-13-0780 | PMID 24343843 Get It

Abstract Cigarette smoking (CS), hormone therapy (HT), and folate intake (FI) are each thought to influence colorectal cancer risk, but the underlying molecular mechanisms remain incompletely defined. The TP53 (p53) protein, encoded by the TP53 tumor-suppressor gene that is commonly mutated in colorectal cancer, can be readily assessed to differentiate biologically distinct colorectal cancer subtypes. In this prospective cohort study, we examined CS-, HT-, and FI-associated colorectal cancer risks by TP53 protein expression level among Iowa Women's Health Study (IWHS) participants. The IWHS recruited 41,836 randomly selected Iowa women, ages 55 to 69 years, with a valid driver's license at study entry in 1986. Self-reported exposure variables were assessed at baseline. Incident colorectal cancer cases were ascertained by annual linkage with the Iowa Cancer Registry. Archived, paraffin-embedded tissue specimens were collected and evaluated for TP53 protein expression by immunohistochemistry. Multivariate Cox regression models were fit to estimate relative risks (RR) and 95% confidence intervals (CI) for associations between CS, HT, or FI and TP53-defined colorectal cancer subtypes. Informative environmental exposure and protein expression data were available for 492 incident colorectal cancer cases: 222 (45.1%) TP53 negative, 72 (14.6%) TP53 low, and 198 (40.2%) TP53 high. Longer duration (>5 years) of HT was inversely associated with TP53 high colorectal cancers (RR, 0.50; 95% CI, 0.27–0.94). No other statistically significant associations were observed. These data support possible heterogeneous effects from HT on TP53-related pathways of colorectal carcinogenesis in older women. Cancer Epidemiol Biomarkers Prev; 23(2); 350–5. ©2013 AACR.
Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10
Charbonneau, Bridget, Block, Matthew S., Bamlet, William R., Vierkant, Robert A., Kalli, Kimberly R., Fogarty, Zachary, Rider, David N., Sellers, Thomas A., Tworoger, Shelley S., Poole, Elizabeth, Risch, Harvey A., Salvesen, Helga B., Kiemeney, Lambertus A., Baglietto, Laura, Giles, Graham G., Severi, Gianluca, Trabert, Britton, Wentzensen, Nicolas, Chenevix-Trench, Georgia, group, for AOCS/ACS, Whittemore, Alice S., Sieh, Weiva, Chang-Claude, Jenny, Bandera, Elisa V., Orlow, Irene, Terry, Kathryn, Goodman, Marc T., Thompson, Pamela J., Cook, Linda S., Rossing, Mary Anne, Ness, Roberta B., Narod, Steven A., Kupryjanczyk, Jolanta, Lu, Karen, Butzow, Ralf, Dörk, Thilo, Pejovic, Tanja, Campbell, Ian, Le, Nhu D., Bunker, Clareann H., Bogdanova, Natalia, Runnebaum, Ingo B., Eccles, Diana, Paul, James, Wu, Anna H., Gayther, Simon A., Hogdall, Estrid, Heitz, Florian, Kaye, Stanley B., Karlan, Beth Y., Anton-Culver, Hoda, Gronwald, Jacek, Hogdall, Claus K., Lambrechts, Diether, Fasching, Peter A., Menon, Usha, Schildkraut, Joellen, Pearce, Celeste Leigh, Levine, Douglas A., Kjaer, Susanne Kruger, Cramer, Daniel, Flanagan, James M., Phelan, Catherine M., Brown, Robert, Massuger, Leon F.A.G., Song, Honglin, Doherty, Jennifer A., Krakstad, Camilla, Liang, Dong, Odunsi, Kunle, Berchuck, Andrew, Jensen, Allan, Lubiński, Jan, Nevanlinna, Heli, Bean, Yukie T., Lurie, Galina, Ziogas, Argyrios, Walsh, Christine, Despierre, Evelyn, Brinton, Louise, Hein, Alexander, Rudolph, Anja, Dansonka-Mieszkowska, Agnieszka, Olson, Sara H., Harter, Philipp, Tyrer, Jonathan, Vitonis, Allison F., Brooks-Wilson, Angela, Aben, Katja K., Pike, Malcolm C., Ramus, Susan J., Wik, Elisabeth, Cybulski, Cezary, Lin, Jie, Sucheston, Lara, Edwards, Robert, McGuire, Valerie, Lester, Jenny, Bois, Andreas du, Lundvall, Lene, Wang-Gohrke, Shan, Szafron, Lukasz M., Lambrechts, Sandrina, Yang, Hannah, Beckmann, Matthias W., Pelttari, Liisa M., Altena, Anne M. Van, Berg, David van den, Halle, Mari K., Gentry-Maharaj, Aleksandra, Schwaab, Ira, Chandran, Urmila, Menkiszak, Janusz, Ekici, Arif B., Wilkens, Lynne R., Leminen, Arto, Modugno, Francesmary, Friel, Grace, Rothstein, Joseph H., Vergote, Ignace, Garcia-Closas, Montserrat, Hildebrandt, Michelle A.T., Sobiczewski, Piotr, Kelemen, Linda E., Pharoah, Paul D.P., Moysich, Kirsten, Knutson, Keith L., Cunningham, Julie M., Fridley, Brooke L., Goode, Ellen L., Vierkant, Robert A. , Bamlet, William R. , Lu, Karen H. , Ramus, Susan J. , Kjær, Susanne K. , Høgdall, Estrid , Høgdall, Claus , Goodman, Marc T. , García‐Closas, Montserrat , Chenevix‐Trench, Georgia , Lubiński, Jan , Nevanlinna, Heli , Olson, Sara H. , Dörk, Thilo , Giles, Graham G. , Severi, Gianluca , Menon, Usha , Terry, Kathryn L. , Tworoger, Shelley S. , Baglietto, Laura , Bogdanova, Natalia , Ekici, Arif B. , Orlow, Irene , Eccles, Diana , Hein, Alexander , Lambrechts, Diether , Jensen, Allan , Brown, Robert , Bandera, Elisa V. , Campbell, Ian , Kiemeney, Lambertus A. , Aben, Katja K.H. , Sieh, Weiva , Fogarty, Zachary C. , Levine, Douglas A. , Kupryjańczyk, Jolanta , Heitz, Florian , Flanagan, James M. , Dansonka‐Mieszkowska, Agnieszka , Menkiszak, Janusz , Pelttari, Liisa M. , Krakstad, Camilla , Trabert, Britton , Sobiczewski, Piotr , Lambrechts, Diether , Szafron, Lukasz M. , Charbonneau, Bridget, Block, Matthew S., Bamlet, William R., Vierkant, Robert A., Kalli, Kimberly R., Fogarty, Zachary, Rider, David N., Sellers, Thomas A., Tworoger, Shelley S., Poole, Elizabeth, Risch, Harvey A., Salvesen, Helga B., Kiemeney, Lambertus A., Baglietto, Laura, Giles, Graham G., Severi, Gianluca, Trabert, Britton, Wentzensen, Nicolas, Chenevix-Trench, Georgia, group, for AOCS/ACS, Whittemore, Alice S., Sieh, Weiva, Chang-Claude, Jenny, Bandera, Elisa V., Orlow, Irene, Terry, Kathryn, Goodman, Marc T., Thompson, Pamela J., Cook, Linda S., Rossing, Mary Anne, Ness, Roberta B., Narod, Steven A., Kupryjanczyk, Jolanta, Lu, Karen, Butzow, Ralf, Dörk, Thilo, Pejovic, Tanja, Campbell, Ian, Le, Nhu D., Bunker, Clareann H., Bogdanova, Natalia, Runnebaum, Ingo B., Eccles, Diana, Paul, James, Wu, Anna H., Gayther, Simon A., Hogdall, Estrid, Heitz, Florian, Kaye, Stanley B., Karlan, Beth Y., Anton-Culver, Hoda, Gronwald, Jacek, Hogdall, Claus K., Lambrechts, Diether, Fasching, Peter A., Menon, Usha, Schildkraut, Joellen, Pearce, Celeste Leigh, Levine, Douglas A., Kjaer, Susanne Kruger, Cramer, Daniel, Flanagan, James M., Phelan, Catherine M., Brown, Robert, Massuger, Leon F.A.G., Song, Honglin, Doherty, Jennifer A., Krakstad, Camilla, Liang, Dong, Odunsi, Kunle, Berchuck, Andrew, Jensen, Allan, Lubiński, Jan, Nevanlinna, Heli, Bean, Yukie T., Lurie, Galina, Ziogas, Argyrios, Walsh, Christine, Despierre, Evelyn, Brinton, Louise, Hein, Alexander, Rudolph, Anja, Dansonka-Mieszkowska, Agnieszka, Olson, Sara H., Harter, Philipp, Tyrer, Jonathan, Vitonis, Allison F., Brooks-Wilson, Angela, Aben, Katja K., Pike, Malcolm C., Ramus, Susan J., Wik, Elisabeth, Cybulski, Cezary, Lin, Jie, Sucheston, Lara, Edwards, Robert, McGuire, Valerie, Lester, Jenny, Bois, Andreas du, Lundvall, Lene, Wang-Gohrke, Shan, Szafron, Lukasz M., Lambrechts, Sandrina, Yang, Hannah, Beckmann, Matthias W., Pelttari, Liisa M., Altena, Anne M. Van, Berg, David van den, Halle, Mari K., Gentry-Maharaj, Aleksandra, Schwaab, Ira, Chandran, Urmila, Menkiszak, Janusz, Ekici, Arif B., Wilkens, Lynne R., Leminen, Arto, Modugno, Francesmary, Friel, Grace, Rothstein, Joseph H., Vergote, Ignace, Garcia-Closas, Montserrat, Hildebrandt, Michelle A.T., Sobiczewski, Piotr, Kelemen, Linda E., Pharoah, Paul D.P., Moysich, Kirsten, Knutson, Keith L., Cunningham, Julie M., Fridley, Brooke L., Goode, Ellen L., Trabert, B , Pelttari, L M , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Kiemeney, Lambertus A , Kjaer, Susanne K , Ramus, Susan J , Tworoger, Shelley S , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Szafron, Lukasz M , Moysich, Kirsten , Orlow, Irene , Campbell, Ian G , Bamlet, William R , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Severi, Gianluca , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Baglietto, Laura , Goodman, Marc T , Bandera, Elisa V.

Mayo Clinic

Cancer Research | November 22, 2013 | Volume: 74 | Issue: 3 | Pages: 852-861

10.1158/0008-5472.can-13-1051 | PMID 24272484 Get It

Abstract A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. Interleukin-1α (IL1A) is both regulated by and able to activate NF-κB, a transcription factor family that induces transcription of many proinflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged SNPs in more than 200 genes in the NF-κB pathway for a total of 2,282 SNPs (including rs17561) for genotype analysis of 15,604 cases of ovarian cancer in patients of European descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studies in the Ovarian Cancer Association Consortium. In this large population, we confirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence interval (CI), 0.76–0.93; P = 0.00075], which remained intact even after excluding participants in the prior study (OR, 0.85; 95% CI, 0.75–0.95; P = 0.006). Considering a multiple-testing–corrected significance threshold of P < 2.5 × 10−5, only one other variant, the TNFSF10 SNP rs6785617, was associated significantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79–0.91; P = 0.00002). Our results extend the evidence that borderline tumors may have a distinct genetic etiology. Further investigation of how these SNPs might modify ovarian cancer associations with other inflammation-related risk factors is warranted. Cancer Res; 74(3); 852–61. ©2013 AACR.
Fibrin Glue to Treat Spinal Fluid Leaks Associated with Intrathecal Drug Systems
Freeman, Eric D., Hoelzer, Bryan C. , Eldrige, Jason S. , Moeschler, Susan M.

Mayo Clinic

Pain Practice | November 21, 2013 | Volume: 14 | Issue: 6 | Pages: 570-576

10.1111/papr.12151 | PMID 24256213 Get It

AbstractIntrathecal drug delivery systems (IDDSs) are used to treat resistant pain states as well as intractable spasticity via medication delivery into the spinal fluid. Risks associated with implantation of these devices include infection, bleeding, intrathecal granuloma formation, and neurologic sequelae similar to other neuraxial procedures. Intrathecal catheter placement creates the additional risk of persistent spinal fluid leak, which can lead to postdural puncture headaches as well as seroma formation and may require subsequent surgical exploration or explantation. This retrospective case series examines 3 patients at a single institution with persistent spinal fluid leak after IDDS placement (and explantation in one case) resulting in headache and/or seroma formation that were treated with epidural fibrin glue.Three patients underwent IDDS implantation with baclofen for spasticity. In 1 patient, a cerebral spinal fluid leak developed at 1‐week postoperatively. After several unsuccessful epidural blood patches and surgical exploration with a catheter revision, she was ultimately treated successfully with a fibrin glue patch. The second patient received an IDDS and did well until a seroma developed 1 year later. He was likewise treated with an epidural fibrin glue patch after 2 failed blood patches. In a third patient, a spinal fluid leak developed after explantation of an IDDS and was treated with an epidural fibrin glue patch as initial therapy.
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium
Herránz, Jesús , Michailidou, Kyriaki , Zamora, M. Pilar , Pérez, José Ignacio Arias , González‐Neira, Anna , Pita, Guillermo , Alonso, M. Rosario, Wang, Qin , Bolla, Manjeet K. , Czene, Kamila , Eriksson, Mikael , Humphreys, Keith , Darabi, Hatef, Li, Jingmei , Hopper, John L. , Apicella, Carmel, Southey, Melissa C. , Chenevix‐Trench, Georgia , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Swerdlow, Anthony J. , Ashworth, Alan , Orr, Nicholas, Schoemaker, Minouk J. , Jakubowska, Anna , Lubiński, Jan , Jaworska–Bieniek, Katarzyna, Durda, Katarzyna, Andrulis, Irene L. , Knight, Julia A. , Glendon, Gord, Mulligan, Anna Marie , Bojesen, Stig E. , Nordestgaard, Børge G. , Flyger, Henrik, Nevanlinna, Heli , Muranen, Taru , Aittomäki, Kristiina, Blomqvist, Carl , Chang‐Claude, Jenny , Flesch‐Janys, Dieter, Vachon, Celine M. , Purrington, Kristen S. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Grip, Mervi, Dunning, Alison M. , Shah, Mitul , Guénel, Pascal , Truong, Thérèse , Sanchez, Marie, Mulot, Claire , Brenner, Hermann , Dieffenbach, Aida Karina, Stegmaier, Christa, Lindblom, Annika , Margolin, Sara , Hooning, Maartje J. , Hollestelle, Antoinette , Collée, J. Margriet, Jager, Agnes , Cox, Angela , Brock, Ian W., Reed, Malcolm , Devilee, Peter , Tollenaar, Robert A.E.M., Seynaeve, Caroline, Haiman, Christopher A., Henderson, Brian E., Schumacher, Fredrick R. , Simard, Jacques , Dumont, Martine , Soucy, Penny, Dörk, Thilo , Bogdanova, Natalia , Hamann, Ute , Rüdiger, Thomas , Ulmer, Hans-Ulrich, Fasching, Peter A. , Häberle, Lothar , Ekici, Arif B. , Beckmann, Matthias W. , Fletcher, Olivia , Johnson, Nichola , dos‐Santos‐Silva, Isabel , Peto, Julian, Radice, Paolo , Peterlongo, Paolo , Peissel, Bernard , Mariani, P., Severi, Gianluca , Baglietto, Laura , Sawyer, Elinor J. , Tomlinson, Ian , Kerin, Michael J. , Miller, Nicola, Marmé, F., Burwinkel, Barbara , Mannermaa, Arto, Kataja, Vesa , Kosma, Veli‐Matti , Hartikainen, Jaana M. , Lambrechts, Diether , Yesilyurt, Betül T., Floris, Giuseppe , Leunen, Karin, Alnæs, Grethe Grenaker, Kristensen, Vessela N. , Børresen‐Dale, Anne‐Lise , García‐Closas, Montserrat , Lissowska, Jolanta , Figueroa, Jonine D. , Schmidt, Marjanka K. , Verhoef, Senno, Rutgers, Emiel J. , Brauch, Hiltrud , Brüning, Thomas , Ko, Yon‐Dschun, Network, The GENICA, TNBCC, The, Yannoukakos, Drakoulis , Malats, Núria , Easton, Douglas F. , Manoukian, Siranoush , Durocher, Francine , Zaffaroni, Daniela , Orr, Nick , Thorne, Heather , Bowtell, David D.L. , Rabstein, Sylvia , Lotz, Anne , Lambrechts, Diether , Milne, Roger L. , Dennis, Joe , Tyrer, Jonathan P. , Eriksson, Mikael , Anton‐Culver, Hoda , Neuhausen, Susan L. , Ziogas, Argyrios , Clarke, Christina A. , Dite, Gillian S. , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Orr, Nicholas, Rudolph, Anja , Seibold, Petra , Wang, Xianshu , Olson, Janet E. , Vachon, Celine M. , Sanchez, Marie, Arndt, Volker , Hooning, Maartje J. , Marchand, Loı̈c Le , Försti, Asta , Giles, Graham G. , Mannermaa, Arto, Chanock, Stephen Jacob , Broeks, Annegien , Network, The GENICA, Couch, Fergus J. , Toland, Amanda Ewart , TNBCC, The, Pharoah, Paul D.P. , Hall, Per N , Benı́tez, Javier , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Peterlongo, Paolo , Swerdlow, Anthony J , Radice, Paolo , Lissowska, Jolanta , Southey, Melissa C , Malats, Nuria , Dunning, Alison M , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Guénel, Pascal , Li, Jingmei , Muranen, Taru A , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Michailidou, Kyriaki , Hartikainen, Jaana M , Bogdanova, Natalia V , Simard, Jacques , Chenevix-Trench, Georgia , Figueroa, Jonine D , Czene, Kamila , Bowtell, David D , Pylkäs, Katri , Yannoukakos, Drakoulis , Devilee, Peter , Manoukian, Siranoush , Lubinski, Jan , Baglietto, Laura , Fletcher, Olivia , Bojesen, Stig E , Purrington, Kristen S , Schoemaker, Minouk J , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J , Orr, Nick

Mayo Clinic

Human Molecular Genetics | November 16, 2013 | Volume: 23 | Issue: 7 | Pages: 1934-1946

10.1093/hmg/ddt581 | PMID 24242184 Get It

Abstract Part of the substantial unexplained familial aggregation of breast cancer may be due to interactions between common variants, but few studies have had adequate statistical power to detect interactions of realistic magnitude. We aimed to assess all two-way interactions in breast cancer susceptibility between 70 917 single nucleotide polymorphisms (SNPs) selected primarily based on prior evidence of a marginal effect. Thirty-eight international studies contributed data for 46 450 breast cancer cases and 42 461 controls of European origin as part of a multi-consortium project (COGS). First, SNPs were preselected based on evidence (P < 0.01) of a per-allele main effect, and all two-way combinations of those were evaluated by a per-allele (1 d.f.) test for interaction using logistic regression. Second, all 2.5 billion possible two-SNP combinations were evaluated using Boolean operation-based screening and testing, and SNP pairs with the strongest evidence of interaction (P < 10−4) were selected for more careful assessment by logistic regression. Under the first approach, 3277 SNPs were preselected, but an evaluation of all possible two-SNP combinations (1 d.f.) identified no interactions at P < 10−8. Results from the second analytic approach were consistent with those from the first (P > 10−10). In summary, we observed little evidence of two-way SNP interactions in breast cancer susceptibility, despite the large number of SNPs with potential marginal effects considered and the very large sample size. This finding may have important implications for risk prediction, simplifying the modelling required. Further comprehensive, large-scale genome-wide interaction studies may identify novel interacting loci if the inherent logistic and computational challenges can be overcome.
Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing
Whiley, Phillip J , Hoya, Miguel de la , Thomassen, Mads , Becker, Alexandra, Pedersen, Inge Søkilde , Montagna, Marco , Menéndez, Mireia , Quiles, Francisco, Gutiérrez‐Enríquez, Sara , Leeneer, Kim De , Tenés, Anna, Montalban, Gemma , Tserpelis, Demis, Yoshimatsu, Toshio F. , Tirapo, Carole, Raponi, Michela , Caldés, Trinidad , Blanco, Ana , Guidugli, Lucia, Garibay, Gorka Ruíz de , Wong, Ming, Tancredi, Mariella, Fachal, Laura , Ding, Yuan Chun , Kruse, Torben A., Lattimore, Vanessa , Kwong, Ava , Chan, Tsun Leung , Colombo, Mara , Vecchi, Giovanni De, Caligo, Maria A. , Baralle, Diana , Lázaro, Conxi , Radice, Paolo , Southey, Melissa C. , Houdayer, Claude , Fackenthal, Jim, Hansen, Thomas van Overeem , Vega, Ana , Dı́ez, Orland , Blok, Rien, Claes, Kathleen , Wappenschmidt, Barbara , Walker, Logan C. , Spurdle, Amanda B. , Brown, Melissa A. , Brandão, Rita D. , Santamariña, Marta , Couch, Fergus J. , Neuhausen, Susan L. , Caligo, Maria A , Spurdle, Amanda B , Vega, Ana , de la Hoya, Miguel , Diez, Orland , Gutiérrez-Enríquez, Sara , Radice, Paolo , Claes, Kathleen B M , Southey, Melissa C , Lazaro, Conxi , Montagna, Marco , Ruiz de Garibay, Gorka , Montalban, Gemma , De Leeneer, Kim , Hansen, Thomas van Overeem , Kwong, Ava , Fachal, Laura

Mayo Clinic

Clinical Chemistry | November 8, 2013 | Volume: 60 | Issue: 2 | Pages: 341-352

10.1373/clinchem.2013.210658 | PMID 24212087 Get It

Abstract BACKGROUND Accurate evaluation of unclassified sequence variants in cancer predisposition genes is essential for clinical management and depends on a multifactorial analysis of clinical, genetic, pathologic, and bioinformatic variables and assays of transcript length and abundance. The integrity of assay data in turn relies on appropriate assay design, interpretation, and reporting. METHODS We conducted a multicenter investigation to compare mRNA splicing assay protocols used by members of the ENIGMA (Evidence-Based Network for the Interpretation of Germline Mutant Alleles) consortium. We compared similarities and differences in results derived from analysis of a panel of breast cancer 1, early onset (BRCA1) and breast cancer 2, early onset (BRCA2) gene variants known to alter splicing (BRCA1: c.135-1G>T, c.591C>T, c.594-2A>C, c.671-2A>G, and c.5467+5G>C and BRCA2: c.426-12_8delGTTTT, c.7988A>T, c.8632+1G>A, and c.9501+3A>T). Differences in protocols were then assessed to determine which elements were critical in reliable assay design. RESULTS PCR primer design strategies, PCR conditions, and product detection methods, combined with a prior knowledge of expected alternative transcripts, were the key factors for accurate splicing assay results. For example, because of the position of primers and PCR extension times, several isoforms associated with BRCA1, c.594-2A>C and c.671-2A>G, were not detected by many sites. Variation was most evident for the detection of low-abundance transcripts (e.g., BRCA2 c.8632+1G>A Δ19,20 and BRCA1 c.135-1G>T Δ5q and Δ3). Detection of low-abundance transcripts was sometimes addressed by using more analytically sensitive detection methods (e.g., BRCA2 c.426-12_8delGTTTT ins18bp). CONCLUSIONS We provide recommendations for best practice and raise key issues to consider when designing mRNA assays for evaluation of unclassified sequence variants.
Functional Assays for Analysis of Variants of Uncertain Significance inBRCA2
Guidugli, Lucia, Carreira, Aura , Caputo, Sandrine M. , Ehlén, Åsa , Galli, Alvaro , Monteiro, Álvaro N.A. , Hansen, Thomas van Overeem , Neuhausen, Susan L. , Couch, Fergus J. , Vreeswijk, Maaike P.G. , Monteiro, Alvaro N , Hansen, Thomas van Overeem

Mayo Clinic

Human Mutation | November 6, 2013 | Volume: 35 | Issue: 2 | Pages: 151-164

10.1002/humu.22478 | PMID 24323938 Get It

Effects of Estrogen on Bone mRNA Levels of Sclerostin and Other Genes Relevant to Bone Metabolism in Postmenopausal Women
Fujita, Koji , Roforth, Matthew M., Demaray, Susan, McGregor, Ulrike, Kirmani, Salman , McCready, Louise K., Peterson, James M., Khosla, Sundeep , Drake, Matthew T. , Monroe, David G. , Khosla, Sundeep

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 30, 2013 | Volume: 99 | Issue: 1 | Pages: E81-E88

10.1210/jc.2013-3249 | PMID 24170101 Get It

Context: Studies in postmenopausal women have shown that estrogen reduces circulating sclerostin levels, but effects of estrogen on skeletal sclerostin mRNA levels are unknown. Objective: The objective of the study was to evaluate the effects of short-term estrogen treatment on bone mRNA levels of sclerostin and other genes relevant to bone metabolism. Design, Setting, and Patients: Needle bone biopsies were obtained from 20 postmenopausal women treated with transdermal estrogen for 3 weeks and 20 untreated controls. Quantitative PCR analyses were used to examine the expression of sclerostin and other genes related to bone metabolism, including 71 additional genes linked to bone density/fracture from genome-wide association studies. Results: Estrogen treatment was associated with lower bone sclerostin mRNA levels (by 48%, P < .05) and with lower (by 54%, P < .01) mRNA levels of the sclerostin-related protein, sclerostin domain-containing protein 1 (SOSTDC1), which is also a Wnt/bone morphogenetic protein inhibitor. Consistent with studies in mice showing that ovariectomy increased nuclear factor-κB (NF-κB) activation, we found that estrogen treatment was associated with a significant reduction in inflammatory genes as a group (P = .028), with bone mRNA levels of NFKB2 and RELB (both encoding proteins in the NF-κB transcription factor complex) being significantly reduced individual genes. Eight of the 71 genome-wide association study-related genes examined were modulated by estrogen (P < .05, false discovery rate < 0.10). Conclusion: In humans, estrogen-induced decreases in two key inhibitors of Wnt/bone morphogenetic protein signaling, sclerostin and SOSTDC1, along with reductions in NF-κB signaling, may be responsible for at least part of the protective effects of estrogen on bone.